A Phase 1/2 interventional study of AGN-241751 and Placebo in Major Depressive Disorder, sponsored by Syndeio Biosciences, Inc. Completed at 5 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-07.
Sponsored by Syndeio Biosciences, Inc · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 323rd largest by enrollment of the 1,323 interventional ones that give a count, is one of 50 that started in 2018, is one of 32 in phase 1/2, and was the 963rd registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 22–60
Baylor College of Medicine · Sites in United States
Ages 18–64
Ohio State University · Sites in United States
Ages 21–65
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 325 · Phase 3 262 · Phase 4 189
First in 1979; this study’s year is marked. 50 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 226 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 1,323 interventional studies, 100 across the 171 observational. Of the 1,156 that completed or were terminated, 584 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
484 of 1,500 have an industry lead sponsor. The 10 most frequent:
Syndeio Biosciences, Inc is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Syndeio Biosciences, Inc has 5 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
99 of the studies in Depressive Disorder, Major with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 99 to your calendar (.ics) → With an account.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of AGN-241751 in participants with Major Depressive Disorder
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Psychiatric and Treatment-Related Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B
Drug: AGN-241751
AGN-241751, oral administration, once per day
Drug: AGN-241751
AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B
Drug: AGN-241751
Placebo, oral administration, once per day in part A. Twice per day (BID) in Part B
Drug: Placebo
AGN-241751 is supplied in tablet form
Placebo is supplied in tablet form
Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group
Efficacy will be measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement. Results are reported as change from baseline in treated group compared to change from baseline in placebo, reported as least squares difference and (standard error) calculated from a mixed model-repeated measures analysis
Time frame: Baseline (Day1) to Day 2
Part B: Change From Baseline in MADRS Score at Day 8 Post the Initial Dose of AGN-241751 (i.e. 1 Day After the Seventh Daily Dose)
Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement.
Time frame: Baseline (Day 1) to Day 8
Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo
Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement.
Time frame: Baseline (Day 1) to Day 22
Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group
Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement. Results are reported as change from baseline in treated group compared to change from baseline in placebo, reported as least squares difference and (standard error) calculated from a mixed model-repeated measures analysis
Time frame: Baseline (Day 1) to Day 21
| Milestone | AGN-241751 3mg Daily | AGN-241751 10mg Daily | AGN-241751 25mg Daily | Placebo Daily | AGN-241751 3mg Two Times Per Day | AGN-241751 25mg Two Times Per Day | Placebo 2 Times Per Day |
|---|---|---|---|---|---|---|---|
| Started | 26 | 26 | 26 | 25 | 40 | 40 | 41 |
| Completed | 25 | 26 | 24 | 25 | 34 | 35 | 36 |
| Not completed | 1 | 0 | 2 | 0 | 6 | 5 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 6 | 4 | 2 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Not reported | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Efficacy will be measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement. Results are reported as change from baseline in treated group compared to change from baseline in placebo, reported as least squares difference and (standard error) calculated from a mixed model-repeated measures analysis
| score on a scale | AGN-241751 3mg Daily | AGN-241751 10mg Daily | AGN-241751 25mg Daily | Placebo Daily | AGN-241751 3mg Two Times Per Day | AGN-241751 25mg Two Times Per Day | Placebo 2 Times Per Day |
|---|---|---|---|---|---|---|---|
| Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group | -9.4 ± 1.57 | -6.7 ± 1.58 | -9.5 ± 1.57 | -9.3 ± 1.61 | — | — | — |
Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement.
| score on a scale | AGN-241751 3mg Daily | AGN-241751 10mg Daily | AGN-241751 25mg Daily | Placebo Daily | AGN-241751 3mg Two Times Per Day | AGN-241751 25mg Two Times Per Day | Placebo 2 Times Per Day |
|---|---|---|---|---|---|---|---|
| Part B: Change From Baseline in MADRS Score at Day 8 Post the Initial Dose of AGN-241751 (i.e. 1 Day After the Seventh Daily Dose) | — | — | — | — | -12.8 ± 1.53 | -10.5 ± 1.52 | -10.9 ± 1.48 |
Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement.
| score on a scale | AGN-241751 3mg Daily | AGN-241751 10mg Daily | AGN-241751 25mg Daily | Placebo Daily | AGN-241751 3mg Two Times Per Day | AGN-241751 25mg Two Times Per Day | Placebo 2 Times Per Day |
|---|---|---|---|---|---|---|---|
| Day 9 | -13.0 ± 1.86 | -13.6 ± 1.87 | -14.1 ± 1.85 | -12.0 ± 1.89 | — | — | — |
| Day 15 | -13.2 ± 1.86 | -13.7 ± 1.87 | -13.2 ± 1.89 | -11.6 ± 1.90 | — | — | — |
| Day 22 | -12.5 ± 1.97 | -11.8 ± 1.91 | -14.5 ± 1.90 | -13.6 ± 1.94 | — | — | — |
Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement. Results are reported as change from baseline in treated group compared to change from baseline in placebo, reported as least squares difference and (standard error) calculated from a mixed model-repeated measures analysis
| score on a scale | AGN-241751 3mg Daily | AGN-241751 10mg Daily | AGN-241751 25mg Daily | Placebo Daily | AGN-241751 3mg Two Times Per Day | AGN-241751 25mg Two Times Per Day | Placebo 2 Times Per Day |
|---|---|---|---|---|---|---|---|
| Day 11 | — | — | — | — | -15.8 ± 1.70 | -15.2 ± 1.72 | -14.0 ± 1.67 |
| Day 14 | — | — | — | — | -17.0 ± 1.76 | -15.3 ± 1.82 | -14.7 ± 1.71 |
| Day 18 | — | — | — | — | -18.3 ± 1.88 | -15.0 ± 1.98 | -16.9 ± 1.86 |
| Day 21 | — | — | — | — | -17.3 ± 1.79 | -16.5 ± 1.84 | -16.5 ± 1.74 |
Collected over Two weeks = 14 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AGN-241751 3mg Daily | 0/26 (0%) | 0/26 (0%) | 6/26 (23.1%) |
| AGN-241751 10mg Daily | 0/26 (0%) | 0/26 (0%) | 8/26 (30.8%) |
| AGN-241751 25mg Daily | 0/26 (0%) | 0/26 (0%) | 6/26 (23.1%) |
| Placebo Daily | 0/25 (0%) | 0/25 (0%) | 3/25 (12%) |
| AGN-241751 3mg Two Times Per Day | 0/41 (0%) | 0/41 (0%) | 15/41 (36.6%) |
| AGN-241751 25mg Two Times Per Day | 0/41 (0%) | 0/41 (0%) | 20/41 (48.8%) |
| Placebo 2 Times Per Day | 0/41 (0%) | 1/41 (2.4%) | 22/41 (53.7%) |
| Event | AGN-241751 3mg Daily | AGN-241751 10mg Daily | AGN-241751 25mg Daily | Placebo Daily | AGN-241751 3mg Two Times Per Day | AGN-241751 25mg Two Times Per Day | Placebo 2 Times Per Day |
|---|---|---|---|---|---|---|---|
| Abortion InducedPregnancy, puerperium and perinatal conditions | 0/26 | 0/26 | 0/26 | 0/25 | 0/41 | 0/41 | 1/41 |
| Event | AGN-241751 3mg Daily | AGN-241751 10mg Daily | AGN-241751 25mg Daily | Placebo Daily | AGN-241751 3mg Two Times Per Day | AGN-241751 25mg Two Times Per Day | Placebo 2 Times Per Day |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 4/26 | 5/26 | 4/26 | 3/25 | 6/41 | 10/41 | 14/41 |
| NauseaGastrointestinal disorders | 2/26 | 3/26 | 2/26 | 0/25 | 1/41 | 6/41 | 2/41 |
| ConstipationGastrointestinal disorders | 0/26 | 0/26 | 0/26 | 0/25 | 3/41 | 2/41 | 3/41 |
| Abnormal DreamsNervous system disorders | 0/26 | 0/26 | 0/26 | 0/25 | 3/41 | 2/41 | 2/41 |
| Back PainMusculoskeletal and connective tissue disorders | 0/26 | 0/26 | 0/26 | 0/25 | 3/41 | 0/41 | 1/41 |
Participants in Part A and Part B were analyzed completely separately.
| Age, Continuous(years) | AGN-241751 3mg Daily | AGN-241751 10mg Daily | AGN-241751 25mg Daily | Placebo Daily | AGN-241751 3mg Two Times Per Day | AGN-241751 25mg Two Times Per Day | Placebo 2 Times Per Day | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 44.2 ± 13.14 | 39.0 ± 13.84 | 41.4 ± 15.03 | 36.2 ± 12.43 | 38.5 ± 12.62 | 40.3 ± 14.21 | 37.7 ± 14.06 | 40.2 ± 13.78 |
| Sex: Female, Male(Participants) | AGN-241751 3mg Daily | AGN-241751 10mg Daily | AGN-241751 25mg Daily | Placebo Daily | AGN-241751 3mg Two Times Per Day | AGN-241751 25mg Two Times Per Day | Placebo 2 Times Per Day | Total |
|---|---|---|---|---|---|---|---|---|
| Part A — Female | 18 | 16 | 18 | 14 | 20 | 14 | 12 | 112 |
| Part A — Male | 8 | 10 | 8 | 11 | 20 | 26 | 29 | 112 |
| Race/Ethnicity, Customized(Participants) | AGN-241751 3mg Daily | AGN-241751 10mg Daily | AGN-241751 25mg Daily | Placebo Daily | AGN-241751 3mg Two Times Per Day | AGN-241751 25mg Two Times Per Day | Placebo 2 Times Per Day | Total |
|---|---|---|---|---|---|---|---|---|
| White | 16 | 14 | 18 | 15 | 12 | 16 | 12 | 103 |
| Black | 9 | 11 | 7 | 8 | 25 | 22 | 26 | 108 |
| Asian | 0 | 0 | 1 | 1 | 0 | 0 | 3 | 5 |
| American Indian or Alaska Native | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 3 |
| Native Hawaiian or Pacific Islander | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Multiple | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 4 |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | AGN-241751 3mg Daily | AGN-241751 10mg Daily | AGN-241751 25mg Daily | Placebo Daily | AGN-241751 3mg Two Times Per Day | AGN-241751 25mg Two Times Per Day | Placebo 2 Times Per Day | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 26 | 26 | 26 | 25 | 40 | 40 | 41 | 224 |
| Montgomery-Asberg Depression Severity (MADRS) score at baseline (prior to first dose)(units on a scale) | AGN-241751 3mg Daily | AGN-241751 10mg Daily | AGN-241751 25mg Daily | Placebo Daily | AGN-241751 3mg Two Times Per Day | AGN-241751 25mg Two Times Per Day | Placebo 2 Times Per Day | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 34.0 ± 4.48 | 35.0 ± 4.51 | 33.3 ± 5.02 | 34.0 ± 4.20 | 34.1 ± 3.62 | 34.2 ± 4.12 | 33.8 ± 5.05 | 34.06 ± 0.509 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2018 to primary completion in Oct 2019, 11 months.
Results were first posted in Jul 2023, 3 years 8 months after primary completion. A results delay was requested in Oct 2020.
Of 31 phase 1/2 interventional studies under Depressive Disorder, Major, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 75. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zelquistinel
Syndeio Biosciences, Inc